APH Alliance Pharma Plc

TIDMAPH

RNS Number : 3628E

Alliance Pharma PLC

29 June 2023

 
 For immediate release    29 June 2023 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

 
 Name of applicant:                                      ALLIANCE PHARMA PLC 
 Names of schemes:                                       a) The Alliance Pharma plc Approved Share Option Plan 2005 
                                                          b) The Alliance Pharma plc Share Option Plan 2006 
                                                          c) The Alliance Pharma plc Company Share Option Plan 2015 
                                                          d) The Alliance Pharma plc Long-Term Incentive Plan 2019 
                                                        -------------------------------------------------------------- 
 Period of return:           From:                       28 December 2022             To:         28 June 2023 
                            --------------------------  ---------------------------  ----------  --------------------- 
 Number of securities originally admitted at date of     25,000,000 ordinary shares of 1p each 
 admission:                                               28 June 2017 
                                                        -------------------------------------------------------------- 
 Balance of unallotted securities under schemes from     a) 149,637 
 previous return:                                         b) 2,551,168 
                                                          c) 9,572,622 
                                                          d) 1,341,116 
                                                        -------------------------------------------------------------- 
 Plus: The amount by which the block schemes have been   a) Nil 
 increased since the date of the last                     b) Nil 
 return (if any increase has been applied for):           c) Nil 
                                                          d) Nil 
                                                        -------------------------------------------------------------- 
 Less: Number of securities issued/allotted under        a) 91,715 
 schemes during period:                                   b) 63,422 
                                                          c) 0 
                                                          d) 0 
                                                        -------------------------------------------------------------- 
 Equals: Balance under schemes not yet issued/allotted   e) 57,922 
 at end of period:                                        f) 2,487,746 
                                                          g) 9,572,622 
                                                          h) 1,341,116 
                                                        -------------------------------------------------------------- 
 
 
 
 Name of contact:               Chris Chrysanthou, Company Secretary 
 Telephone number of contact:   Tel. +44 (0)1249 705166 
                               ------------------------------------- 
 

For further information:

 
 Alliance Pharma plc                            + 44 (0)1249 466966 
 Cora McCallum, Head of Investor Relations 
  & Corporate Communications                    + 44 (0)1249 705168 
 ir@allianceph.com 
 
                                                    + 44 (0)20 7466 
 Buchanan                                                      5000 
 Mark Court / Hannah Ratcliff 
 alliancepharma@buchanan.uk.com 
 
 Numis Securities Limited (Nominated Adviser        + 44 (0)20 7260 
  and Corporate Broking)                                       1000 
 Freddie Barnfield / Duncan Monteith / Sher 
  Shah 
 
                                                    + 44 (0)20 7597 
 Investec Bank plc                                             5970 
 Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company . Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions .

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRNKCBNPBKKCAB

(END) Dow Jones Newswires

June 29, 2023 02:00 ET (06:00 GMT)

Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Apr 2024 a Mag 2024

Grafico Azioni Alliance Pharma (LSE:APH)
Storico
Da Mag 2023 a Mag 2024